USPTO grants new CRISPR-Cas9 patent to University of California

The US Patent and Trademark Office (USPTO) has granted a new CRISPR-Cas9 patent to the University of California (UC), the University of Vienna and Emmanuelle Charpentier, marking the fifth consecutive week that the USPTO has approved a new patent in their CRISPR portfolio.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USPTO grants University of California 20th CRISPR patent

2 January 2020 The US Patent and Trademark Office has granted the University of California its 20th US patent on CRISPR-Cas9 gene-editing technologies.

Genetics

CRISPR: A licence to heal

1 October 2019 As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood.

Americas

USPTO revives fight over CRISPR patents

27 June 2019 The US Patent and Trademark Office has revived the dispute between the Broad Institute of MIT and Harvard and the University of California, Berkeley over which first invented the CRISPR gene-editing technology.

More on this story

Americas

USPTO grants University of California 20th CRISPR patent

2 January 2020 The US Patent and Trademark Office has granted the University of California its 20th US patent on CRISPR-Cas9 gene-editing technologies.

Genetics

CRISPR: A licence to heal

1 October 2019 As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood.

Americas

USPTO revives fight over CRISPR patents

More on this story

Americas

USPTO grants University of California 20th CRISPR patent

2 January 2020 The US Patent and Trademark Office has granted the University of California its 20th US patent on CRISPR-Cas9 gene-editing technologies.

Genetics

CRISPR: A licence to heal

1 October 2019 As all sides prepare for a milestone case in the battle over rights to CRISPR/Cas9, LSIPR’s Rory O’Neill finds the CEO of ERS Genomics in a positive mood.

Americas

USPTO revives fight over CRISPR patents